Selected article for: "acute respiratory disease and mab monoclonal antibody"
Author: Qiu, Hongjie; Sun, Shihui; Xiao, He; Feng, Jiannan; Guo, Yan; Tai, Wanbo; Wang, Yufei; Du, Lanying; Zhao, Guangyu; Zhou, Yusen
Title: Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection
  • Cord-id: gn812sh4
  • Document date: 2016_6_14
    • ID: gn812sh4
    Snippet: Middle East respiratory syndrome coronavirus (MERS-CoV) is continuously spreading and causing severe and fatal acute respiratory disease in humans. Prophylactic and therapeutic strategies are therefore urgently needed to control MERS-CoV infection. Here, we generated a humanized monoclonal antibody (mAb), designated hMS-1, which targeted the MERS-CoV receptor-binding domain (RBD) with high affinity. hMS-1 significantly blocked MERS-CoV RBD binding to its viral receptor, human dipeptidyl peptidas
    Document: Middle East respiratory syndrome coronavirus (MERS-CoV) is continuously spreading and causing severe and fatal acute respiratory disease in humans. Prophylactic and therapeutic strategies are therefore urgently needed to control MERS-CoV infection. Here, we generated a humanized monoclonal antibody (mAb), designated hMS-1, which targeted the MERS-CoV receptor-binding domain (RBD) with high affinity. hMS-1 significantly blocked MERS-CoV RBD binding to its viral receptor, human dipeptidyl peptidase 4 (hDPP4), potently neutralized infection by a prototype MERS-CoV, and effectively cross-neutralized evolved MERS-CoV isolates through recognizing highly conserved RBD epitopes. Notably, single-dose treatment with hMS-1 completely protected hDPP4 transgenic (hDPP4-Tg) mice from lethal infection with MERS-CoV. Taken together, our data suggest that hMS-1 might be developed as an effective immunotherapeutic agent to treat patients infected with MERS-CoV, particularly in emergent cases.

    Search related documents:
    Co phrase search for related documents
    • accession number and lung infection: 1, 2
    • accession number and lung tissue: 1
    • acute sars cov respiratory syndrome coronavirus and additional case: 1, 2, 3, 4, 5, 6, 7
    • acute sars cov respiratory syndrome coronavirus and live mers cov infection: 1
    • acute sars cov respiratory syndrome coronavirus and lu describe: 1
    • acute sars cov respiratory syndrome coronavirus and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute sars cov respiratory syndrome coronavirus and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung infection tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute sars cov respiratory syndrome coronavirus and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung injury extent: 1
    • acute sars cov respiratory syndrome coronavirus and lung interstitial tissue: 1, 2
    • acute sars cov respiratory syndrome coronavirus and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and mab control: 1
    • acute sars cov respiratory syndrome coronavirus and mab development: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and mab humanize: 1
    • additional case and lung injury: 1, 2
    • luciferase activity and lung injury: 1, 2, 3
    • luciferase activity and lung tissue: 1